Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Abstract : ABSTRACT: Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.
https://www.hal.inserm.fr/inserm-00491423 Contributor : Yves Le SterConnect in order to contact the contributor Submitted on : Friday, June 11, 2010 - 3:47:52 PM Last modification on : Tuesday, July 5, 2022 - 9:16:01 AM Long-term archiving on: : Friday, September 17, 2010 - 1:26:40 PM
Charles Theillet. What do we learn from HER2-positive breast cancer genomic profiles?. Breast Cancer Research, BioMed Central, 2010, 12 (3), pp.107. ⟨10.1186/bcr2571⟩. ⟨inserm-00491423⟩